Investigational drug · Phase 2
parsaclisib
Also called: INCB050465
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma, B-Cell Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
36
Any phase or sponsor naming "parsaclisib"
First trial start
2020
Aug 3, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "parsaclisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Hodgkins Lymphoma
- Diffuse Large B-cell Lymphoma
- B-Cell Malignancies
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "parsaclisib" as an intervention, largest first.
- To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)Pivotal-lookingTerminated
Incyte CorporationIncyte (INCY)
NCT04551066 · 252 participants · Start May 24, 2021 · Primary completion Aug 3, 2023
Drug: parsaclisib; ruxolitinib and 1 more · For: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis and 1 more
Sites: Anchorage, Alaska; Phoenix, Arizona; Berkeley, California · 177 sites in all
- To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Pivotal-lookingTerminated
Incyte CorporationIncyte (INCY)
NCT04551053 · 177 participants · Start May 26, 2021 · Primary completion Aug 16, 2023
Drug: parsaclisib; ruxolitinib and 1 more · For: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis and 1 more
Sites: Berkeley, California; Fresno, California; Los Angeles, California · 177 sites in all
Incyte CorporationIncyte (INCY)
NCT03235544 · 162 participants · Start Nov 20, 2017 · Primary completion Apr 30, 2024
Drug: Parsaclisib · For: Lymphoma
Sites: Birmingham, Alabama; Santa Rosa, California; Aurora, Colorado · 103 sites in all
Incyte CorporationIncyte (INCY)
NCT02646748 · 159 participants · Start Jan 25, 2016 · Primary completion Nov 7, 2019
Drug: Pembrolizumab; itacitinib and 1 more · For: Colorectal Cancer (CRC); Endometrial Cancer; Melanoma and 8 more
Sites: San Francisco, California; Santa Monica, California; Washington D.C., District of Columbia · 17 sites in all
Incyte CorporationIncyte (INCY)
NCT02559492 · 142 participants · Start Nov 2015 · Primary completion Sep 10, 2018
Drug: Itacitinib; Epacadostat and 2 more · For: Solid Tumors
Sites: Duarte, California; Denver, Colorado; New Haven, Connecticut · 11 sites in all
Incyte CorporationIncyte (INCY)
NCT03126019 · 126 participants · Start Mar 14, 2018 · Primary completion Feb 26, 2021
Drug: Parsaclisib · For: Lymphoma
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 83 sites in all
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruiting
Incyte CorporationIncyte (INCY)
NCT04509700 · 112 participants · Start Aug 3, 2020 · Primary completion Nov 5, 2026
Drug: Parsaclisib; parsaclisib + itacitinib and 2 more · For: B-Cell Malignancies
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 105 sites in all
- A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)Completed
Incyte CorporationIncyte (INCY)
NCT03144674 · 110 participants · Start Dec 18, 2017 · Primary completion Jan 15, 2021
Drug: Parsaclisib · For: Lymphoma
Sites: Birmingham, Alabama; Tempe, Arizona; Redondo Beach, California · 86 sites in all
Incyte CorporationIncyte (INCY)
NCT02018861 · 88 participants · Start Sep 22, 2016 · Primary completion Apr 12, 2021
Drug: Parsaclisib; Itacitinib and 4 more · For: B-Cell Malignancies
Sites: Birmingham, Alabama; Ann Arbor, Michigan; Detroit, Michigan · 7 sites in all
Incyte CorporationIncyte (INCY)
NCT02265510 · 83 participants · Start Sep 10, 2014 · Primary completion Feb 27, 2019
Drug: INCB052793; gemcitabine and 10 more · For: Solid Tumors; Advanced Malignancies; Metastatic Cancer
Sites: Birmingham, Alabama; West Hollywood, California; New Haven, Connecticut · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- All-Oral PI3Kδ and HDAC Inhibition with Parsaclisib Plus Chidamide and Step-Down Maintenance in Relapsed or Refractory Peripheral T-Cell Lymphoma: A Phase Ib Trial.
Luo X, Yan Z, Fang W, et al. · MedComm (2020) 2026
- Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.
Kiladjian JJ, Borate U, Abruzzese E, et al. · Oncologist 2026
- The Path Forward in MF: Small Molecules in the Limelight.
Abruzzese E, Trawinska MM, Bernardi S, et al. · Cancers (Basel) 2026
- Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
Izutsu K, Fukuhara N, Yuda J, et al. · Cancer Sci 2026
- Management of autoimmune hemolytic anemia.
Barcellini W, Fattizzo B · Hematology Am Soc Hematol Educ Program 2025
- Bullous Pemphigoid Develops Independently of DAP12.
Pigors M, Patzelt S, Brudey M, et al. · Biomolecules 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.